Haemoband Surgical has compiled a comprehensive Clinical Evidence Report — a full synthesis of every published study, independent cohort, and contextual clinical trial in which the Haemoband or Haemoband-PLUS device has been used or cited. The findings are clear, and they’re worth sharing with every surgical procurement team, colorectal consultant, and clinical director in your network.
Here’s what the evidence shows.
A Device Built on Three Layers of Evidence
The Haemoband-PLUS clinical case doesn’t rest on a single study. It is supported by three distinct and complementary layers of evidence.
Layer 1: Device-specific published studies
The primary device study — Alubaidi, Clarke, Jamil & Ghareeb (2016), published in Surgical Science — evaluated single-session multi-band ligation using the Haemoband-PLUS in patients presenting with two or more haemorrhoids. The result: 90% of patients were successfully treated in a single session. This directly validates the pre-loaded four-band design that distinguishes the Haemoband-PLUS from every single-band competitor on the market.
Layer 2: Large independent real-world cohort
In 2022, Dekker et al. published a retrospective cohort study in the Annals of Coloproctology (PMC9021858). This was not a manufacturer-commissioned study — it was an independent, tertiary-centre analysis of 327 patients with Grade III haemorrhoids. The Haemoband disposable ligator was used for all 182 RBL procedures in the cohort, over a median 44-month follow-up period.
The findings: patient-reported outcomes were equivalent to haemorrhoidectomy, with significantly fewer complications. This is the kind of real-world, independent evidence that procurement committees and clinical governance teams ask for — and it names the Haemoband by device.
Layer 3: A 2,635-patient prospective series
Komporozos et al. (2021), published in the International Journal of Colorectal Disease, followed 2,635 consecutive patients undergoing rubber band ligation using suction ligators. At two-year follow-up, 84.5% remained asymptomatic. This is the largest prospective RBL series referenced in our evidence base, and it reinforces the performance profile of suction-based ligation — the exact mechanism of the Haemoband-PLUS.
Why the Mechanism Matters: Suction vs. Forceps
Not all rubber band ligators are equal. The Haemoband-PLUS uses a suction-based mechanism — and this matters clinically.
A prospective RCT by Bayer et al. (Techniques in Coloproctology, 2005) compared suction and forceps ligation head-to-head in 100 patients. Suction ligation produced:
- Immediate post-procedure pain VAS 3.08 vs. 6.08 with forceps (p<0.001)
- Analgesic use 2.4 vs. 4.5 tablets (p=0.003)
- Intra-procedure bleeding events 5 vs. 25 (p<0.001)
The evidence shows that suction is clinically superior for patient comfort and procedural safety.
The Broader Evidence Context
RBL is the most widely used non-surgical treatment for Grade I–III haemorrhoids globally. The wider literature — including Cochrane meta-analyses and multi-centre RCTs across 10 Dutch hospitals — confirms that RBL produces equivalent patient-reported outcomes to haemorrhoidectomy, with far fewer complications and a return to work time of 1 day vs. 9 days for surgery.
For Grade III haemorrhoids, RBL is an appropriate first-line intervention before surgery is considered — a positioning that puts the Haemoband-PLUS squarely at the front of the clinical pathway.
What This Means for You
- 4 published studies citing or using the Haemoband device
- Over 3,000 patients across the combined evidence base
- Independent tertiary-centre data (not manufacturer-funded)
- Equivalent outcomes to haemorrhoidectomy with fewer complications
- A 2–3 minute procedure vs. 10 minutes for traditional forceps ligation
The device is FDA 510(k) cleared, CE marked, ISO certified, and protected by 4 international patents. The evidence is there. The clinical story is clear.
About the Haemoband-PLUS
The Haemoband-PLUS Multi-Ligator is a single-use, pre-loaded suction rubber band ligator developed in Belfast, Northern Ireland by Consultant Surgeon Essam Ghareeb. First launched in 2005 as the world’s first device of its kind, it features four individually moulded latex-free bands, a dual-action trigger for single-operator use, and a transparent nozzle tip for direct visualisation before firing. Distributed globally across Europe, the Americas, the Middle East, and Asia-Pacific.
